Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19

Phase 3

Recruiting

• Conditions: COVID-19.; U07.1 - COVID-19; COVID-19

• Registration Number: IRCT20200428047228N1
• Lead Sponsor: Quality Improvement of Intensive Care Research Center- Shahid Beheshti University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

a-Respiratory Rate(RR)=30 /min
b-SpO2<93% on room air
c-PaO2/FIO2<300
d-CT scan Involvement>50%
e-Diagnosis confirmed by CPR or CT scan
f-Age more than 18 years

Exclusion Criteria

a-G6PD Deficiency
b-QT interval more than 450 milliseconds
c-myasthenia gravis
d-Pregnancy- Breast Feeding
e-Severe Renal or Hepatic Failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
o fever for 3 days. Timepoint: Daily. Method of measurement: Medical Records.;-SpO2>93%. Timepoint: daily. Method of measurement: Medical Records.;CXR observation. Timepoint: After the end of the treatment period. Method of measurement: Observation.

Secondary Outcome Measures

Name	Time	Method
-All cause Mortality. Timepoint: once. Method of measurement: Medical Records.;-Need to Mechanical ventilation. Timepoint: Daily. Method of measurement: Medical Records.;Drug Adverse Effect. Timepoint: Daily. Method of measurement: Medical Records.